| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | BIO-GENE TECHNOLOGY LTD: Notice of Annual General Meeting/Proxy Form | 1 | ASX | ||
| 29.10. | BIO-GENE TECHNOLOGY LTD: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 19.10. | Bio-Gene Technology Receives $343,000 R&D Tax Incentive Boost | 1 | Finance News Network | ||
| 19.10. | BIO-GENE TECHNOLOGY LTD: Bio-Gene Receives $343,000 R&D Tax Incentive | - | ASX | ||
| 12.10. | BIO-GENE TECHNOLOGY LTD: Date of 2026 Annual General Meeting | - | ASX | ||
| 07.10. | BIO-GENE TECHNOLOGY LTD: Flavocide efficacy results against deer ticks published | 1 | ASX | ||
| 28.08. | BIO-GENE TECHNOLOGY LTD: Corporate Governance Statement | 1 | ASX | ||
| BIO-GENE TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 28.08. | BIO-GENE TECHNOLOGY LTD: Appendix 4G | 1 | ASX | ||
| 28.08. | BIO-GENE TECHNOLOGY LTD: Appendix 4E and 2026 Annual Report | 1 | ASX | ||
| 27.08. | BIO-GENE TECHNOLOGY LTD: Change in substantial holding | 1 | ASX | ||
| 27.08. | BIO-GENE TECHNOLOGY LTD: Change in substantial holding | 1 | ASX | ||
| 10.08. | BIO-GENE TECHNOLOGY LTD: Notification regarding unquoted securities - BGT | - | ASX | ||
| 10.08. | BIO-GENE TECHNOLOGY LTD: Change of Director's Interest Notice x 4 | 5 | ASX | ||
| 10.08. | BIO-GENE TECHNOLOGY LTD: Placement Completed and Cleansing Notice | 1 | ASX | ||
| 10.08. | BIO-GENE TECHNOLOGY LTD: Application for quotation of securities - BGT | 2 | ASX | ||
| 10.08. | BIO-GENE TECHNOLOGY LTD: Application for quotation of securities - BGT | 9 | ASX | ||
| 10.08. | BIO-GENE TECHNOLOGY LTD: Application for quotation of securities - BGT | - | ASX | ||
| 05.08. | BIO-GENE TECHNOLOGY LTD: Results of Meeting | 1 | ASX | ||
| 31.07. | BIO-GENE TECHNOLOGY LTD: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 06.07. | BIO-GENE TECHNOLOGY LTD: Notice of Extraordinary General Meeting/Proxy Form | - | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,440 | +3,60 % | NanoRepro legt H1-Zahlen vor: Warum die Plattformstrategie trägt | ||
| PALATIN TECHNOLOGIES | 4,610 | +0,66 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| BRAIN BIOTECH | 2,460 | -0,81 % | Brain Biotech im Check: 9M-Zahlen und Syngenta-Deal - reicht der Schwung? | ||
| AAP IMPLANTATE | 1,430 | -0,69 % | aap Implantate - Aktie vor Neubewertung? CEO und COO im Interview: "Die Basis steht, jetzt schalten wir auf Wachstum." | Eine spannende Sondersituation zeichnet sich derzeit bei der aap Implantate AG (ISIN: DE000A3H2101) ab: Nach Jahren der Restrukturierung und hohen regulatorischen Aufwendungen hat der Berliner Spezialist... ► Artikel lesen | |
| CO.DON | 0,005 | -35,71 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 0,700 | -1,41 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| CLINUVEL | 4,272 | -0,90 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| BIO-GATE | 2,060 | +3,00 % | Original-Research: Bio-Gate AG (von BankM AG): Kaufen | Original-Research: Bio-Gate AG - von BankM AG
10.11.2026 / 12:44 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,150 | +0,59 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EDITAS MEDICINE | 1,510 | +1,00 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| EXELIXIS | 58,98 | +0,03 % | Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | ||
| EVONEXT | 2,420 | -1,63 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26 | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26
16-Nov-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| GERON | 0,800 | +0,98 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |